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Abstract 
Genital infections with Chlamydia trachomatis continue to be a major health problem worldwide.   While some 
individuals clear their infection (presumed to be the result of an effective Th1 / gamma-interferon response), 
others develop chronic infections and some are prone to repeat infections. In females in particular, chronic 
asymptomatic infections are common and can lead to pelvic inflammatory disease and infertility.  Recent 
studies suggest that the genital tract microbiota could be a significant factor and explain person-to-person 
variation in C. trachomatis infections. One hypothesis suggests that C. trachomatis can use its trpBA genes to 
rescue tryptophan from indole, which is a product of anaerobic members of the genital tract microbiota. 
Women with particular microbiota types, such as seen in bacterial vaginosis, have increased numbers of 
anaerobes, and this would enable the chlamydia in these individuals to overcome the host’s interferon-gamma 
attempts to eliminate it, resulting in more repeat and/or chronic infections.   
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Chlamydia trachomatis Infections 
Chlamydia trachomatis is an obligate intracellular bacterium that is the causative agent of sexually transmitted 
infection in humans and is a widespread public health concern because of its high prevalence. Worldwide, an 
estimated 131 million sexually transmitted C. trachomatis infections occur each year [1]. A significant 
proportion (up to 80%) of infections in women are asymptomatic, and in the absence of active screening and 
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treatment, most infections go undetected.  If left untreated, about 10% of Chlamydia infections in women will 
progress to pelvic inflammatory disease (PID) [2]. Other complications such as endometritis, ectopic pregnancy 
and infertility can also occur [3]. Individuals vary in their response to C. trachomatis infections. In some 
individuals, infections can self-resolve in about one year on average (20-54% of cases) [4–7]. However, in others 
(23-30% of cases), they can become repeatedly infected, two or more times, in the 12 months following initial 
diagnosis and treatment [8–12]. It is generally assumed that a strong T-helper 1 (Th1) and interferon-gamma 
(IFN-γ) response can lead to spontaneous resolution in a percentage of patients, however the majority of 
patients do not spontaneously resolve their infections [4–7,13]. It has also been shown in the murine model 
that antibiotic treatment can suppress the host protective immune response [14]. This observation has been 
referred to as the "arrested immunity hypothesis" [15], in which, according to a mathematical model, suggest 
that early treatment of C. trachomatis infection increases population susceptibility to reinfections [16], 
presumably by interfering with the development of protective immune response.  In addition to parasite and 
host effects, it has recently been proposed that the bacteria in the vaginal microbiota might play a key role in 
the outcome of C. trachomatis infections.  Antibiotics used to treat the Chlamydia might also interfere with a 
the healthy bacterial equilibrium in the genital tract [17–19], specifically causing a decrease in the prevalence of 
commensal Lactobacillus spp., that are known to have inhibitory effects on pathogenic bacteria.  [20–23]. The 
most recent hypothesis suggests that the anaerobe component of the vaginal microbiota (not the lactobacilli 
per se) might play a key role.  In this review we summarize the many factors that contribute to a healthy versus 
diseased state in which Chlamydia could successfully colonize the female genital tract (Figure 1).   
Chlamydia Has a Unique Developmental Cycle.  
C. trachomatis is classified into two biovars; the trachoma biovar which includes ocular and urogenital strains 
(A-K) and the lymphogranuloma venereum LGV biovar (L1-L3) [24]. The ocular strains (serovars A - C) are 
characterized by localized infection of the epithelial surface of the conjunctiva.  Serovars D-K are responsible for 
infections in the urogenital tract, especially in the endocervix [25]. Chlamydia has a unique biphasic 
developmental cycle, which alternates between two distinct morphological forms, the elementary bodies (EB) 
and the reticulate bodies (RB) [26]. When infection occurs, the metabolically inert EBs, attach to and stimulate 
uptake by the host cell. Upon entry, the internalized EBs remain within a membrane-bound, host-derived 
parasitophorous vacuole, termed an inclusion, where they differentiate into larger, non-infectious but the 
metabolically active RB form [27–29]. RBs undergo proliferation by binary fission and inclusion growth. After 8 
to 12 rounds of multiplication, the RBs convert back into EBs. At 30-84 hours post-infection, depending on the 
infecting species, the infectious EBs are released from the host cell, predominantly via lysis, to attach to the 
neighboring cells and initiate another cycle (Figure 2A). However, under stressful growth conditions caused by a 
range of factors, such as host immunological response, antibiotic treatment or nutrient starvation [30–36], the 
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developmental cycle is disturbed and the EBs convert to enlarged, non-infectious, aberrant bodies (AB), until 
the stress factor is removed [28] (Figure 2B). This so called persistent state is defined as a ‘viable but non-
cultivable growth stage’ [29,30]. Chlamydial persistence in vitro has been characterized in many studies [30–
36], however very few groups have been able to isolate aberrant forms from clinical samples [34], confirming 
that chlamydial persistence in vivo needs further investigation. 
 
The Immune Response and Progression to Disease 
Women who acquire new infections or are unable to fully clear their current infection, are more prone to 
diseases such as PID, tubal factor infertility and ectopic pregnancy [2,37–41]. Progression to these sequelae is 
thought to be the outcome of immuno-pathological inflammatory responses that result in tissue disruption, 
fibrosis and scarring [39,42,43]. The adaptive immune response to C. trachomatis infection is characterized by 
the production of significant numbers of T cells infiltrating the infected area. One of the most important cellular 
immune responses in the development of protective immunity against chlamydial infection is characterized by 
antigen specific IFN-γ- secreting CD4+ and CD8+ T cells. Studies in the murine model have reported that the 
resolution of a genital chlamydial infection depends on IFN-γ- producing CD4+ Th1 cells [44–47] to control or 
eliminate an infection. However, upon reinfection or chronic infection, host cell release of chemokines could 
lead to recruitment of Chlamydia-specific immune cells to magnify the response. The release of proteases, 
clotting factors and tissue growth factors from infected host cells and infiltrating inflammatory cells results in 
tissue damage and scarring [43]. These devastating sequelae are the result of chronic, immunopathogenic 
responses to the Chlamydia and are associated with Th1 and Th17 cells (reviewed by Hafner et al. [48]). High 
expression of Th2-type cytokines such as IL-10, IL-1α, IL-6, IL-4 and TNF-α (Th1) were also associated with 
disease and increased risk of pathological sequelae in trachoma and urogenital C. trachomatis infections [49–
51]. These findings highlight the theory of 'the immunological paradigm for pathogenesis' where T cell 
responses necessary for host defence may also cause collateral tissue damage [3]. The reasons why C. 
trachomatis can cause extended infections, lasting from months to years in the face of an immune response, is 
not well understood, but suggests an array of sophisticated parasite adaptation and/or evasion mechanisms.  
There are many factors that influence the initial chlamydial infection and its progress, including the host 
immune response, hormonal changes throughout the menstrual cycle, bacterial communities colonizing the 
genital tract, as well as co-infections with other sexually transmitted infections (STIs; Figure 1).  
Figure 1 goes here. 
Tryptophan Depletion via IFN-γ Response and C. trachomatis Evasion Mechanism 
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IFN-γ is a critical cytokine for the innate and adaptive immune response against a wide range of viral and 
bacterial infections, including Chlamydia. Among its many roles in the host immune response, IFN-γ has been 
associated with protection and immune activation against viral, bacterial and protozoal infections [52–54], 
activation of macrophages, induction of Class ll MHC [53] and involvement in autoimmune diseases [55]. IFN-γ 
also activates the expression of indoleamine 2,3-dioxygenase (IDO). IDO is an enzyme which catabolizes the 
amino acid L- tryptophan into kynurenine (Figure 2B), depleting the host cell’s pool of tryptophan [25,56–59]. 
IFN-γ is well known as an anti-chlamydial agent, causing inhibition of growth and development of the 
Chlamydia, primarily because C. trachomatis is a tryptophan auxotroph [25,58–60]. Although high 
concentrations of IFN-γ in vitro are lethal to the Chlamydia, sub-inhibitory concentrations [58] can drive the 
Chlamydia into its persistence form [30,59], as evident by aberrant non-infectious bodies (Figure 2B). It has 
been suggested that C. trachomatis has developed a mechanism to evade the host’s immune defence strategy, 
by retaining a subset of the genes in the tryptophan synthesis pathway: the trpA, trpB and trpR genes (Figure 
2B). It has been shown in vitro that these genes enable the urogenital strains of C. trachomatis to synthesize or 
rescue tryptophan from indole [24,70,74]. This set of genes was found to be upregulated in a cell culture 
infected with C. trachomatis and treated with IFN-γ [58]. These genes are located on a region of the chlamydial 
genome referred to as the ‘plasticity zone’. This chromosomal region varies between chlamydial species and 
has undergone increased levels of genetic variation, compared to other regions of the chromosome [63]. 
Different Chlamydia species contain different parts of the tryptophan biosynthesis pathway, with the exception 
of C. trachomatis serovar MoPn and C. pneumoniae, that do not encode any of the trp genes [60]. In vitro 
experiments show that the effect of IFN-γ on C. trachomatis growth and survival varies between the different 
serovars, as well as their ability to recover after the tryptophan starvation stress [25,57]. For example, C. 
trachomatis genital strains can be rescued after IFN-γ treatment using exogenous indole.  However, the ocular 
serovars, which have inactivating mutations in their trpBA genes, are therefore not able to synthesize 
tryptophan from indole [64].  
Figure 2 goes here   
Unique Challenges and Opportunities of Bacteria Living in the Female Genital Tract  
The human body is a complex ecosystem, which functions in association with diverse microbial populations. 
The female vaginal tract, as with other mucosal sites in the body, is in contact with the external environment, 
providing a route of entry and colonization for microorganisms.  A healthy host-vaginal microbiota is termed a 
holobiont, in which a functional equilibrium is established through mutualism between the host and the 
resident microbes. This healthy equilibrium acts to provide a barrier to both new colonization by pathogenic 
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organisms as well as overgrowth of non-commensal organisms [65,66]. In most reproductive age women, 
Lactobacillus species are numerically dominant in the lower genital tract [17,67–69]. Using molecular-based 
techniques to characterise the different communities, the microbiota can be conveniently classified into four or 
five community state types (CSTs) [69,70]. The groups are classified based on the dominant specific 
Lactobacillus species;  (i) L. iners, (ii) L. crispatus, (iii) L. gasseri and/ or (iv) L. jensenii, while the last group (v) is 
characterized by a lower abundance of Lactobacillus, and a higher proportion of various anaerobic bacterial 
species [69,70]. Lactobacillus spp. are considered to have a key protective role in the vaginal flora by lowering 
the pH through lactic acid production [23], as well as inhibition of other pathogenic bacteria by producing a 
range of bacteriostatic and bactericidal compounds [71]. A L. crispatus dominant microbiota is generally 
considered to be the most stable flora, providing efficient protection against invading pathogenic 
microorganisms and is associated with the lowest pH levels among all CST groups [69]. In addition, women 
dominated by L. crispatus have been suggested to have higher lactic acid production and a healthier 
equilibrium, whereas L. gasseri and L. iners are more conducive to the occurrence of abnormal microflora 
[67,72]. Studies have shown that vaginal bacterial communities vary among women, are species rich, and 
include bacteria that were not previously detected by traditional culture-based methods [17,67,69,73] (Table 
1). However, despite many of the studies revealing the composition of the species in the vaginal tract, a better 
understanding of the relationships between the different bacterial species and their function in this complex 
eco-system is still needed. 
 
Composition of the Vaginal Microbiome as a Major Impact on Health and Disease  
 
It is generally accepted that a healthy vaginal microbiota contains higher numbers of Lactobacillus spp. The 
replacement of the Lactobacillus spp. with facultative and/or strict anaerobes, such as Gardnerella vaginalis, 
Prevotella spp., Peptostreptoccocus spp., Mobiluncus spp., and a wide range of other fastidious and uncultivable 
bacterial species (Table 1), can result in the switch from normal vaginal microbiota to dysbiosis and bacterial 
vaginosis (BV). In the ‘diseased’ state, such as BV, the bacterial community dynamics can change rapidly, and 
are usually individual specific [74].  BV is associated with higher pH conditions and an increased risk of acquiring 
sexually transmitted infections (STIs) such as herpes, HIV and C. trachomatis [17,75,76]. Lactobacillus spp. have 
been observed to inhibit in vitro growth of numerous bacterial species through the production of lactic acid 
[77,78], including time and concentration-dependent killing of C. trachomatis [20].  Interestingly, some of the 
bacterial species that are associated with BV are also lactic acid producers, including Megasphaera, 
Streptococcus and Atopobium. The production of lactic acid seems to be conserved in different bacterial 
communities regardless of their association with the host state of health or disease, implicating it as a key 
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factor in multiple ecological systems and functions. There are many factors that could affect the microbial 
communities in the vagina (Figure 1), causing significant changes over short periods of time [79]. For example, 
after antibiotic treatment, there was a rapid decrease in the presence of facultative and strict anaerobic 
bacteria, and an increase in Lactobacillus spp. However, this effect was a short-lived, lasting for only 2-4 weeks 
post treatment [74].  
 
Table 1 goes here.  
 
Influences on the Microbial Communities in the Female Genital Tract 
 
The human microbiota is influenced by the host life style including diet, alcohol consumption, drugs and 
antibiotic use (Reviewed by Relman 2012) [80], smoking [81], hygiene, hormonal contraception, sexual life style 
and the number of sex partners [82] . The microbiome composition is also influenced by the host genotype, 
immune response and the environment (Figure 1).  
 
Hormones 
The immune response, sex hormones, and the vaginal microbiota, are tightly connected to each other and 
influenced by fluctuations during the female menstrual cycle. Sex hormones co-ordinate cell trafficking and 
immune activation [83], and can contribute to the susceptibility of the innate and acquired immunity to 
bacterial and viral infections [84]. Symbiotic vaginal bacteria such as Lactobacillus spp. have also been shown to 
be under hormonal influence [85].  Studies have shown that during a window of 7-10 day during the secretory 
phase of the menstrual cycle, important components of innate, humoral and cell-mediated immunity are 
suppressed by estradiol and/or progesterone, enhancing the potential for viral and bacterial infections [86]. 
During this phase, estradiol levels transiently decline and then increase concurrently with progesterone. 
Estradiol and progesterone prepare the uterus for implantation during  the second half of the menstrual cycle 
by providing an adequate vascular supply and subsequent nutrients [86]. Along with the reproductive function, 
sex hormones regulate the transport of immunoglobulin A (IgA) and IgG, the levels of cytokines, the expression 
of TLR genes [87] and the distribution of immune cells and antigen presentation in the genital tissues during the 
reproductive cycle [88]. Fluctuations in the Th1/Th2 cytokine profile across the menstrual cycle, with lower 
levels of IFN-γ during the luteal phase [89], could lead to a compromised immune system, while fighting against 
chlamydial infection. Furthermore, higher numbers of antibody-secreting B cells, along with higher levels of IgA 




Optimal pH levels vary among the different species of in vitro cultured commensal vaginal Lactobacillus spp. 
The optimal growth conditions and maximum bacteriocin production of the vaginal isolate, L. salivarius were 
recorded with an initial pH of 6.5 at 37°C [92]. The highest viable cell count for the vaginal isolate L. crispatus, 
was obtained at pH 5.5; whereas at pH levels below 3.5 or above 7.5,  cell growth was inhibited [93]. In L. 
acidophilus culture, the best growth conditions and maximum lactic acid production were obtained with an 
initial pH of 6.5 at 37°C. Under these optimal growth conditions L. acidophilus was able to inhibit uropathogenic 
Escherichia coli in vitro [94]. Glycogen is also associated with pH and Lactobacillus spp. colonization in the 
genital tract. Quantification of glycogen from vaginal secretions has shown higher levels of free glycogen 
correlated with lower pH levels and higher levels of L. crispatus and L. jensenii colonization, but not L. iners [95]. 
At the onset of puberty, Lactobacillus spp. prevalence increases in the female genital tract and the pH level 
decreases [95]. These changes were suggested to be dependent on estrogen levels, because the low pH and 
Lactobacillus spp. colonization in the vagina occur at the same time as when estrogen levels are increasing [96].   
Gorodeski et al. suggested that estrogen contributes to the acidification of the vaginal pH by upregulation of 
proton secretion via the apical membrane of vaginal ectocervical cells in their epithelial cell line model [97]. 
Several other studies also showed that estrogen contribute to the acidification of the vagina (Reviewed in [98]). 
However, a recent study showed that free glycogen levels, measured in the genital fluids of 7 pre-menopausal 
women, were negatively associated with pH and progesterone, while estrogen levels had no significant 
correlation with free glycogen [99].   
The C. trachomatis Plasmid, Glycogen and the Vaginal Microbiome 
Virtually all C. trachomatis isolates carry a highly conserved, 7.5 kb plasmid, which encodes eight coding 
sequences (CDS) [100–102]. Plasmid-deficient Chlamydia organisms are generally attenuated by removal of the 
plasmid [115]. C. trachomatis and C. muridarum plasmid-deficient strains failed to activate Toll like receptor-2 
(TLR2) and show reduced virulence [105]. In a recent study investigating the transcriptional profiling of a 
plasmid-cured trachoma strain of C. trachomatis, in human epithelial cells, genes related to host cell 
inflammatory response and immune avoidance were not upregulated in comparison to the strain containing 
the plasmid, suggesting a crucial role for the plasmid in trachoma pathogenesis and virulence [106]. Plasmid-
deficient strains of trachoma have been proposed as a live-attenuated vaccine when used to vaccinate non-
human primates [107,108]. In addition, mature inclusions of the mutant strain with a deletion in the CDS5 and 
6 regions on the plasmid resulted in altered morphology and a 'black hole' phenotype [100]. Recent progress 
also shows that the plasmid gene pgp4 is responsible for the lytic exit of the organisms from the host cell during 
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the developmental cycle, and thereby is necessary for the infection of neighboring host cells [109]. Despite the 
great progress in the chlamydial plasmid studies, many of its biological characteristics are still not fully 
understood.  The older literature shows that the chlamydial plasmid is linked to glycogen synthesis and 
accumulation [110]. C. trachomatis possess all the essential genes for glycogen synthesis (mrsA, glgC, glgA, 
glgB), as well as genes required for glycogen degradation (glgX and glgP) [111].  Although the glycogen 
synthase gene, glgA, is located on the chlamydial chromosome, the plasmid apparently controls its 
transcription levels [112]. Naturally occurring plasmid-less, and plasmid-cured strains of C. trachomatis are 
lacking visible glycogen accumulation and present reduced transcript levels of the glgA gene [112].  When a 
wild type C. trachomatis strain was grown in a medium containing various glucose concentrations, low 
concentrations limited the Chlamydia growth in vitro, as well as its ability to accumulate glycogen [103]. 
Glycogen is thought to support Lactobacillus spp. colonization in vivo, as many studies report correlation of 
increasing glycogen levels  in female vaginal secretions, reaching a peak at mid-cycle, with a subsequent 
increase in lactic acid producing microbes in the vagina and an acidic pH [66,95,113]. However, most of the 
Lactobacillus spp. isolates found in the vaginal flora cannot utilize glycogen [114]. It was found recently that α-
amylase is present in the vaginal fluids, and can break down glycogen to small carbohydrates,  which the 
Lactobacillus spp. can use as an energy source [115]. A more recent study by the same group reported that a 
low pH actually limits the α-amylase enzyme by more than 50%, but was still able to maintain Lactobacillus 
growth [116].  
Indole as a Key Factor in the Microbial Equilibrium 
Indole is an important molecule due to its diverse biological roles associated with biofilm, drug resistance, 
plasmid stability and microbial communities [117–122]. Many bacterial species, both Gram-negative and Gram-
positive, can produce indole in large quantities. Although it has been known for over 100 years [123] that 
bacteria can produce indole, only recently have studies discovered its biological role as an intercellular signaling 
molecule [117,122,124]. Indole levels increase drug resistance in Salmonella enterica, which cannot produce 
indole, through the induction of four multidrug efflux pumps [119]. It was also found that in the presence of the 
antibiotic ampicillin, the production of indole in E. coli was 22-fold higher than the control [125]. However, 
indole represses the genes encoding the mexGHI-opmD multidrug efflux pump in Pseudomonas aeruginosa, 
and also represses the genes involved in quorum sensing-regulated virulence factors [118]. A report by Lee  
[117] shows that indole represses biofilm by decreasing motility in E. coli through SdiA, however, in direct 
contrast, it increases biofilm production in P. aeruginosa.  
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Differences in virulence, drug resistance, and biofilm formation, induced by indole, can have major 
consequences on health and disease. For example,  the role of indole was recently investigated in the gastro-
intestinal tract, and was found to have probiotic properties [126]. Bansal et al. found that indole increases 
epithelial-cell tight junction resistance and attenuates indicators of inflammation, such as decreasing TNF-α 
gene expression and the proinflammatory chemokine IL-8. They also showed that exposure to physiologically 
relevant indole concentrations had a beneficial result on the human enterocyte cell line HCT-8, including 
strengthening the mucosal barrier and mucin production. Their previous work [127] showed that indole 
secreted from commensal E. coli in human feces also reduced pathogenic E. coli chemotaxis, motility and 
attachment to epithelial cells in vitro. In contrast, it is known that indole and other indole compounds, play a 
role in carcinogenesis as they have genotoxicity properties, and have been linked to colonic cancer [128–130]. 
These findings emphasize the important role of all factors including, bacterial composition, signal molecule 
production, immune response and various host factors in a single ecosystem.  
How Chlamydia Can Utilize the Microbiome to Overcome Host Immune Attack 
When chlamydial particles, which contain LPS, contact a target epithelial cell in the genital tract, they stimulate 
an innate IFN-γ cascade which the host utilizes in an attempt to eliminate the invading pathogen. The triggered 
IFN-γ cascade, among other processes, upregulates the host cell enzyme IDO, which converts available 
tryptophan to kynurenine. This has the effect of depleting the intracellular pools of the key amino acid, 
tryptophan.  Of course, tryptophan is an essential amino acid and the human genital strains of C. trachomatis 
are, somewhat surprisingly, tryptophan auxotrophs. Chlamydia has evolved two mechanisms to overcome this 
host immune attack. First, they slow down their metabolism and hide out by entering a persistence state [28–
30]. While the initial trigger is unknown, the organisms are prevented from undergoing binary fission and their 
differentiation from RBs to EBs is subsequently halted, however, there is continued genome replication and 
mRNA synthesis [29,30,36,58]. This results in chlamydial aberrant bodies inside the inclusion that are able to 
survive without tryptophan due to their lowered metabolism. The second mechanism, applicable only to the 
genital strains of C. trachomatis in the female genital tract, involves using the pool of extracellular indole 
produced by some bacterial species (e.g. Prevotella spp., Peptostreptococcus spp., Peptoniphilus spp., 
Porphyromonas spp.), that are present in the fornix, cervix and lower region of the vaginal canal [70,131]. The C. 
trachomatis genital strains (D-K) have retained just the single enzyme, TrpBA, in the tryptophan biosynthetic 
pathway, which enables them to convert indole (produced by the microbiota) to tryptophan. This proposed 
mechanism is well described by Morrison [132] and was supported by several other reports arguing that some 
bacteria from the vaginal microbiome, especially those that are associated with BV, are able to produce indole 
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using their tnaA gene, which, in a symbiotic-like arrangement, has driven the chlamydial urogenital strains to 
retain their ability to synthesize back rescue tryptophan [25,34,58,61]. In addition, in vivo examination of 
women infected with C. trachomatis revealed higher levels of indole in their endocervical secretions (159-
278mM) [34]. When screening the vaginal microbial flora of reproductive age women, it was shown that 
women with specific anaerobic bacterial communities, combined with higher pH and lower prevalence of lactic 
acid producing bacteria, are associated with an increased risk of STIs, including Chlamydia [61,69]. While this 
eukaryotic strategy of restricting tryptophan for invading bacterial pathogens as a means of eliminating them, is 
not unique, Chlamydia’s strategy of utilizing the other microbiota bacteria as a source of indole to overcome 
this host strategy does seem to be particularly resourceful. 
Indole has many important roles as an interkingdom signaling molecule and has also been shown to have 
contradictory effects when associated with various species of bacteria. Lactobacillus spp. are an essential part 
of the gastrointestinal tract flora, due to their health promoting properties. Studies show that Lactobacillus spp.  
strains, dead or alive, can absorb indole efficiently, and even cause lower genotoxicity of indole after the 
interaction [129]. In addition, a high abundance of gut Lactobacillus was found to be associated with IDO1 
inhibition and an increase in Th17 levels in simian immunodeficiency virus (SIV)-infected macaques [134]. IDO is 
known for its immunosuppressive function and long-term self-tolerance effects [135]. Consequent to 
downstream effects of the IDO activity, tryptophan depletion inhibits T cell proliferation and induces apoptosis 
[136].  
What is the evolutionary benefit of the trpBA set of genes to the Chlamydia urogenital strains? While only a 
small relative percentage of the commensal vaginal tract bacteria can produce indole, and the species that do 
produce indole are mostly commensal gut bacteria (Table 1). Studies in animals show that Chlamydia can reside 
in the gastrointestinal tract for long periods of time, probably in a chronic or persistent state, and often without 
any pathological or even immunological response (reviewed by Rank et al. [137]). Horizontal transfer between 
hosts, via the oral-fecal route has been recorded as well, while shedding infectious chlamydial particles through 
feces is highly prevalent in livestock and other animal models. Whereas most data in regards to rectal C. 
trachomatis infections was reported in  high risk patients such as men who have sex with men, recent studies 
report a high prevalence in women as well [138,139]. A study in two Canadian sexual health clinics found that 
82.4% (n= 433) of the C. trachomatis positive patients were rectal positive, while 30% of Chlamydia cases were 
positive solely at the rectal site [139]. In addition, in this study the authors found that there was no association 
between patients reporting anal intercourse and having rectal Chlamydia infection, suggesting transfer from 
the genital tract to the rectal site. Indole concentrations in the gastrointestinal tract are high, due to 
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commensal gut bacteria (such as E. coli) that are able to produce indole via their tnaA gene [126,140]. One 
explanation for the existence of the trpBA genes in the urogenital strains of C. trachomatis could be related to 
their site/s of infection. While still speculative, it is possible that Chlamydia has found a niche residing in the 
gastrointestinal tract, hiding away from the immune system in a persistent form, while being able to survive 
using indole provided by the gut microbiota. This might result in a reservoir of chlamydial particles in the 
gastrointestinal tract/rectal site (particularly in females) that could potentially cross-infect the vaginal site.  
Whether indole is the key factor which is responsible for the evasion of C. trachomatis from the host immune 
mechanism via IFN-γ, or it is the combined conditions in the female genital tract that allows the Chlamydia to 
take advantage of the fragile equilibrium of bacteria and metabolic products in this disease state, is unknown.  
A high abundance of lactobacilli will result in lower levels of indole, lower pH, and the ability to efficiently 
eliminate chlamydial infection via the IFN-γ host response. However, an altered microbiome with less 
lactobacilli and more non-lactic acid producers, will lead to higher indole concentrations, which subsequently 
could enable the Chlamydia to overcome IFN-γ effect. 
Concluding Remarks 
C. trachomatis continues to be a major health burden worldwide, with STI infection rates increasing rather than 
decreasing. Hence, there is a continuing need for improved therapeutics, including an effective vaccine as well 
as novel treatment options. Perhaps not surprisingly, given that C. trachomatis is a successful colonizer of the 
female genital tract, it has evolved to make use of the host’s microbiota at this site to supplement its own 
capabilities to overcome host immune attack. This seems to be a unique adaptive strategy, but one that is 
clearly successful for this obligate intracellular pathogen. As we continue to understand how this holobiont 
interaction functions, it does open up new possibilities for treatment (see Outstanding Questions). Vaccines 
could potentially target points in this tryptophan rescue pathway (e.g. using the Chlamydia-specific TrpBA 
protein as a vaccine candidate), perhaps in conjunction with traditional membrane protein vaccine target 
strategies. However, it does also suggest that strategies to manipulate the vaginal microbiota, such as 
modifying the balance between beneficial lactobacilli and indole-producing anaerobes, might be useful. The use 
of indole antagonists, applied directly to the vaginal site, in conjunction with manipulation of the microbiota, 
might also be beneficial. Finally, the question of cross infection of the vaginal site via the gastrointestinal tract 
(which contains high levels of indole producing bacteria) and the potential for the gastrointestinal tract to be a 
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Table 1. Common Commensal, Symbiotic, and Pathogenic Vaginal Bacteria and Their Association with Health or Disease  
Species Healthya Dysbiosis Indoleb Role Species Healthy Dysbiosis Indole Role 
Peptostreptococcus 
anaerobius 





+1 +2 - Gut bacteria 
Propionibacterium 
acnes 





+2 +4 + 
Commensal oral and 
vaginal bacteria 





+2 +3 + 









+1 +3 - Oral bacteria 
Staphylococcus 
saprophyticus 
+3 +1 - 
Commensal 
vaginal bacteria 
Prevotella bivia +1 +5 - Vaginal pathogen 
Klebsiella  
pneumoniae 
+1 +5 - Pathogen Prevotella disiens +1 +5 - Vaginal pathogen 
Bacteroides 
 fragilis 
+1 +4 - 
Commensal gut 
bacteria 
Prevotella oris +2 +2 - 
Commensal oral and 
vaginal bacteria 
Bacteroides bivius +2 +4 - 
Vaginal 
pathogen 
Prevotella oralis +2 +2 - 









+2 +3 - Pathogen 
Mobiluncus  
curtisii 
+1 +4 - 
Vaginal 
pathogen 
Prevotella amnii +1 +4 - Vaginal pathogen 
Mobiluncus  
mulieris 





+2 +3 - Oral bacteria 
Atopobium vaginae +1 +4 - 
Vaginal 
pathogen 
Sneathia amnii +2 +4 - Vaginal pathogen 
Megasphaera 
elsdenii 





+2 +4 - Vaginal pathogen 
Mycoplasma 
hominis 





+2 +4 - Vaginal pathogen 
Gardnerella 
vaginalis 





+1 +4 + 
Commensal gut 
bacteria 



































+1 +5 - 
Commensal gut 
bacteria 




















+3 +1 - 
Commensal 
bacteria 
Parvimonas micra +2 +4 - 
Oral and vaginal 
pathogen 





















+3 +3 + 
Commensal oral gut 
and vaginal bacteria 
Streptococcus 
sanguis 


















































+2 +3 - Vaginal bacteria 
Lactobacillus 
acidophilus 
+4 +1 - 
Symbiotic gut, oral 
and vaginal bacteria 
Anaerococcus 
octavius 
















+4 +1 - 
Symbiotic oral, gut 
and vaginal bacteria 
Anaerococcus 
prevotii 






+4 +1 - 
Symbiotic oral, gut 
and vaginal bacteria 
Anaerococcus 
vaginalis 





+4 +1 - 









+4 +1 - 
Symbiotic gut oral 
and vaginal bacteria 
Fusobacterium 
nucleatum 

























+4 +1 - 









+4 +1 - 
Symbiotic oral gut 
and  vaginal bacteria 
aWhether a species contributes to health or dysbiosis is indicated by a scale from +1 to +5.  At the lower end of the scale, +1 indicates 
that this species is not associated to health or dysbiosis at all, while +5 means the species is highly associated with health or dysbiosis.   
bWhether a species is capable of producing indole is indicate by ‘+’, those that are not are shown by ‘-‘.   
